Anixa Biosciences' (ANIX) Buy Rating Reiterated at D. Boral Capital

Key Points

• Anixa Biosciences' stock has received a "buy" rating from D. Boral Capital, with a price target of $10.00, indicating a potential upside of 235.57% from its previous close.
• Wall Street Zen upgraded Anixa's rating from "sell" to "hold," and three research analysts currently rate the stock as a "buy" with an average price target of $9.00.
• Insider trading activity includes Director Lewis H. Titterton, Jr. acquiring 10,000 shares at $3.08 each, marking a 1.06% increase in ownership, while insiders collectively bought 35,000 shares in the last 90 days.

D. Boral Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX - Free Report) in a report issued on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $10.00 price target on the stock.

Separately, Wall Street Zen upgraded shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research report on Friday, June 6th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $9.00.

Anixa Biosciences Price Performance

Shares of ANIX stock traded down $0.02 during midday trading on Tuesday, reaching $2.93. 102,241 shares of the company traded hands, compared to its average volume of 59,534. The firm's 50 day simple moving average is $3.10 and its two-hundred day simple moving average is $2.97. Anixa Biosciences has a 1-year low of $2.07 and a 1-year high of $4.20. The firm has a market cap of $94.38 million, a PE ratio of -8.37 and a beta of 0.58.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its quarterly earnings results on Wednesday, September 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. As a group, research analysts anticipate that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the company's stock in a transaction dated Thursday, July 31st. The stock was acquired at an average cost of $3.08 per share, with a total value of $30,800.00. Following the purchase, the director directly owned 953,334 shares in the company, valued at approximately $2,936,268.72. This trade represents a 1.06% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have purchased 35,000 shares of company stock worth $110,700. Company insiders own 25.30% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ANIX. Jane Street Group LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $67,000. Focus Partners Wealth purchased a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $162,000. Millennium Management LLC purchased a new position in shares of Anixa Biosciences during the 4th quarter worth approximately $26,000. Private Advisor Group LLC purchased a new stake in Anixa Biosciences in the 1st quarter worth approximately $35,000. Finally, Marshall Wace LLP purchased a new stake in Anixa Biosciences in the 2nd quarter worth approximately $39,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.